Clinical Trial

Verastem Oncology is preparing to show its hand with VS-7375, a novel dual-action KRAS G12D inhibitor. Can its unique science disrupt a crowded market?

New Phase 3 data for Takeda's oveporexton shows it treats the root cause of narcolepsy, not just symptoms. A key FDA decision looms this year.

New clinical trial results for XWRAP® show a significant leap in healing diabetic ulcers, positioning Applied Biologics as a formidable player in a challenging field.

New data reveals elevated cortisol in over 75% of hard-to-treat diabetes patients, paving the way for a novel drug to tackle treatment resistance.

A new partnership between Klick Labs and Mayo Clinic aims to detect disease using your voice. But what does this mean for the future of our health systems?

A single AML patient's journey to a stem cell transplant after treatment with CER-1236 offers a glimmer of hope, but is it a breakthrough or a mirage?

For decades, patients with advanced chondrosarcoma had no options. Now, a new drug's journey to the FDA offers a lifeline and a lesson in medical neglect.

Legend Biotech's stunning trial results for an 'in vivo' CAR-T therapy could make advanced cancer treatment faster, safer, and accessible to all.

With a landmark therapy for Sanfilippo Syndrome nearing the FDA, Spruce adds veteran marketing and finance chiefs. A look at the talent behind the transition.

Phase 1 data for Marea Therapeutics’ MAR002 suggests a potential new era for acromegaly treatment, promising better control with far fewer injections.

Amid new Ebola fears, one biotech's rapid C1 platform promises 15-day biologics, eyeing a $25B market beyond just pandemic response. But can it deliver?

Tiziana Life Sciences’ chairman just increased his massive stake. We analyze if this is a vote of confidence in its novel MS drug or a risky bet on a fragile biotech.

A missed clinical trial endpoint is often the end. For Elicio Therapeutics, a deeper data dive reveals a potential path forward for a high-need patient group.

Lexeo Therapeutics finalizes a pivotal trial for its Friedreich ataxia gene therapy, leveraging a novel trial design and accelerated FDA pathway.

New data reveals an oral drug can halt severe hereditary angioedema attacks in minutes, promising a future free from needles and fear for thousands.

Aussie biotech ENA Respiratory secures crucial US patents for its novel immune modulator, signaling a major strategic move in the multi-billion dollar fight against COPD.

A Dutch biotech is in late-stage trials for nizubaglustat, a drug targeting rare, fatal neurological disorders. A look at the science, strategy, and hope.

A massive 15,000-patient study on an existing therapy could upend respiratory care, combat antibiotic resistance, and deliver a bottom-line windfall.

New data shows remarkable response rates for epcoritamab in a vulnerable patient group with limited options, signaling a potential paradigm shift in first-line lymphoma care.

Sanofi's latest FDA nod for Tzield isn't just a new drug approval; it's a strategic shift from symptom management to disease modification in Type 1 Diabetes.